Atlas Genetics Completes $27.3M Series B Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Infectious disease test development firm Atlas Genetics announced this week the completion of a Series B financing round that raised £16.9 million ($27.3 million).

The funds, to be drawn down over three years, will be used to accelerate the launch of Atlas' Velox point-of-care products for chlamydia and gonorrhea, as well as for the development of other tests and to expand the immunoassay capability of the Velox system, the Bristol, UK-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.